However, patients who received EA demonstrated notable reductions in fasting blood sugar (FBS), insulin levels, lipid profile markers, including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL), as well as inflammatory mediators, specifically TNF-α and IL-1β, and insulin resistance indices. This evidence concerns the gene IL1B and Insulin resistance.